查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014469

子宫内膜异位症治疗市场：依治疗方法、给药途径、最终用户和分销管道划分－2026-2032年全球市场预测

Endometriosis Treatment Market by Treatment Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，子宫内膜异位症治疗市场价值将达到 32.7 亿美元，到 2026 年将成长至 35.1 亿美元，到 2032 年将达到 54.8 亿美元，复合年增长率为 7.65%。

主要市场统计数据
基准年 2025 32.7亿美元
预计年份：2026年 35.1亿美元
预测年份 2032 54.8亿美元
复合年增长率 (%) 7.65%

全面概述了塑造现代子宫内膜异位症治疗生态系统的不断发展的临床方法、患者路径和相关人员的优先事项。

子宫内膜异位症是一种复杂的慢性妇科疾病，其临床需求多样，且需要长期治疗。近年来，该领域在诊断方法、患者期望、医疗服务管道和治疗方法创新方面都发生了显着变化。这些变化要求临床医生、保险公司、製药公司和医疗服务提供者重新评估现有的诊疗实践，并适应以及时诊断、个体化管理和全面患者支持为核心的新环境。

重建子宫内膜异位症的诊断路径、照护模式和治疗方案：检验快速的临床、技术和病患相关变化。

由于临床实践的进步、技术的普及、保险覆盖范围的变化以及患者社群活动的日益活跃等多种因素，子宫内膜异位症的治疗格局正在改变。临床上，人们越来越重视早期发现，并更明确地需要整合多面向介入措施，例如根据需要结合荷尔蒙疗法、疼痛管理和微创手术。同时，诊断辅助工具和数位化分流工具正在缩短患者转诊至专科医生的时间，从而重塑患者进入治疗流程的地点和时间。

分析美国 2025 年的关税措施及其对供应链、筹资策略和子宫内膜异位症患者治疗的连锁影响。

关税调整等政策措施会对药品和医疗设备的整个供应链产生连锁反应。美国2025年宣布的关税措施尤其受到参与子宫内膜异位症治疗的利害关係人的关注。关税带来的成本压力可能导致供应商选择和采购惯例的改变，进而影响子宫内膜异位症治疗中使用的活性成分、成品药和手术耗材的采购。这些变化可能会增加依赖进口的供应链的管理复杂性，并促使企业采取区域筹资策略。

深入了解决定子宫内膜异位症临床优先事项和服务提供的治疗领域、资产回报率 (ROA)、医疗保健环境和通路。

有效的细分能够识别临床需求的差异点以及可以改善营运的领域。就治疗类型而言，子宫内膜异位症的治疗涵盖辅助疗法、荷尔蒙疗法、疼痛管理和手术治疗。荷尔蒙疗法包括Aromatase抑制剂、促性腺激素释放激素促效剂、促性腺激素释放激素拮抗剂、口服避孕药和黄体素等，每种药物的疗效、耐受性和监测需求各不相同。疼痛管理策略包括使用非类固醇消炎剂（NSAIDs）和鸦片类药物。 NSAIDs通常以双氯芬酸钠、Ibuprofen和萘普生等药物为代表，而鸦片类药物通常包括可待因和氢可酮衍生物。这些药物的选择需要遵循不同的安全监测和处方规范。

对美洲、欧洲、中东和非洲以及亚太地区的临床实务、报销架构和病患就医状况进行区域分析，比较子宫内膜异位症的现况。

区域趋势对子宫内膜异位症的诊疗方式和取得途径有显着影响，各大区域在诊疗模式、法规环境和支付方政策方面有显着差异。美洲地区通常兼具公立和私立保险公司，拥有集中化的专科中心，微创手术技术的应用日益普及。同时，新药疗法的可近性取决于保险公司的政策和与区域供应商的关係。相较之下，欧洲、中东和非洲（EMEA）地区的国家医疗保健体系、监管时间表和报销规则呈现出多样化且错综复杂的局面，导致新治疗方法的采用率各不相同，对不孕症预防方法的重视程度也存在差异。

为领导者提供具体建议，以加速子宫内膜异位症的诊断、优化治疗途径、加强供应链和改善患者照护。

实际可行且优先的措施将有助于各机构加速改善子宫内膜异位症的诊疗水平。首先，应增加对临床医生和基层医疗人员的培训投入，以减少诊断延误，并确保始终遵循指南建议的转诊途径。早期发现能够简化诊疗流程，并拓展治疗选择。其次，应透过强调真实世界疗效、生活品质指标和疗效比较，使实证策略与保险公司的优先事项保持一致，从而支持关于保险覆盖范围和纳入处方药清单的讨论。

对研究框架、资料收集和检验过程以及用于深入了解子宫内膜异位症治疗的分析方法进行清晰的说明。

本研究采用结构化、多维度的方法，确保研究结果的稳健性和可靠性。关键的定性资料包括对临床医生、采购负责人和患者权益组织代表的详细访谈，并辅以同行评审的临床研究、监管指南和临床实践指南的文献综述。透过交叉比对这些讯息，检验了主题分析结果，并识别出临床实践和营运决策中的通用模式。

旨在为改善子宫内膜异位症的诊断、医疗保健服务和患者预后，对关键发现和意义进行全面总结，以便优先考虑相关人员。

总之，此综合分析结合了临床、营运和商业性观点，明确了策略重点。诊断延迟、治疗方案可用性差异以及供应链脆弱性被认为是影响患者体验和系统表现的持续性挑战。为应对这些挑战，结合临床医生教育、实证实践、弹性采购和以患者为中心的服务设计等协作策略，是实现持续改进的最有希望的途径。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 子宫内膜异位症治疗市场（依治疗方法划分）

  • 辅助疗法
  • 荷尔蒙疗法
    • Aromatase抑制剂
    • GnRH促效剂
    • GnRH拮抗剂
    • 口服避孕药
    • 黄体素
  • 疼痛管理
    • NSAIDs
      • 双氯芬酸钠
      • Ibuprofen
      • 萘普生
    • 阿片类药物
      • 可待因
      • 氢可酮
  • 手术治疗

第九章 子宫内膜异位症治疗市场：依给药途径划分

  • 注射药物
  • 口服
  • 外用

第十章 子宫内膜异位症治疗市场：依最终使用者划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十一章 子宫内膜异位症治疗市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 子宫内膜异位症治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 子宫内膜异位症治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 子宫内膜异位症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国子宫内膜异位症治疗市场

第十六章 中国子宫内膜异位症治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Anika Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Beijing Biote Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Ferring International Center SA
  • Gedeon Richter Plc
  • Janssen Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Merck & Co., Inc.
  • Myovant Sciences Ltd.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • ObsEva SA
  • Pfizer Inc.
  • Repros Therapeutics Inc.
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4348D129FA88

The Endometriosis Treatment Market was valued at USD 3.27 billion in 2025 and is projected to grow to USD 3.51 billion in 2026, with a CAGR of 7.65%, reaching USD 5.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.27 billion
Estimated Year [2026] USD 3.51 billion
Forecast Year [2032] USD 5.48 billion
CAGR (%) 7.65%

Comprehensive introduction to evolving clinical approaches, patient pathways, and stakeholder priorities shaping modern endometriosis treatment ecosystems

Endometriosis is a complex, chronic gynecologic condition that drives diverse clinical needs and long trajectories of care. Over recent years, the field has experienced substantive changes in diagnostic approaches, patient expectations, care delivery pathways, and therapeutic innovation. These shifts require clinicians, payers, manufacturers, and care providers to reassess established routines and adapt to an environment where timely diagnosis, individualized management, and holistic patient support are paramount.

The introduction situates readers at the intersection of clinical practice and health system dynamics. It synthesizes contemporary challenges such as diagnostic delays, variability in surgical and medical management, and the increasing prominence of patient-reported outcomes. It also highlights the drivers of change, including technology-enabled diagnostics, new pharmacologic mechanisms, and evolving reimbursement pressures. By framing the topic across clinical, operational, and commercial dimensions, the narrative sets expectations for strategic priorities, stakeholder trade-offs, and implementation barriers that will be explored in subsequent sections.

In sum, this introductory perspective aims to equip decision-makers with a concise orientation to the current landscape, clarifying why integrated strategies that bridge clinical evidence, supply continuity, and patient-centered services are essential to improving long-term outcomes and operational performance.

Examination of rapid clinical, technological, and patient shifts reshaping diagnostic pathways, care delivery models and therapeutic choices in endometriosis care

The landscape of endometriosis treatment is shifting under the combined influence of clinical advances, technology diffusion, payer recalibration, and more engaged patient communities. Clinically, there is a clearer emphasis on earlier recognition and on integrating multimodal interventions that combine hormonal management, pain control, and minimally invasive surgery when indicated. Concurrently, diagnostic adjuncts and digital triage tools are starting to reduce time to specialist referral, reshaping where and when patients enter care pathways.

On the commercial and operational side, manufacturers and providers are adapting to more differentiated therapeutic portfolios and variable reimbursement environments. Payers and health systems are prioritizing interventions that demonstrably reduce downstream resource utilization and improve quality of life, prompting deeper scrutiny of comparative effectiveness and real-world evidence. Patient advocacy and shared decision-making are also redefining value frameworks: patients increasingly weigh symptom control, fertility preservation, and quality-of-life impacts when evaluating therapy options.

Taken together, these transformative shifts compel stakeholders to reevaluate product development strategies, provider education, and access initiatives. Successful actors will align clinical evidence generation with pragmatic implementation plans that account for evolving diagnostic workflows, heterogeneous care settings, and rising expectations for patient-centered outcomes.

Analysis of US tariff measures in 2025 and their cascading effects on supply chains, procurement strategies, and patient access to endometriosis therapies

Policy levers such as tariff changes can ripple through pharmaceutical and device supply chains, and the announced United States tariff measures for 2025 warrant careful attention from stakeholders involved in endometriosis care. Tariff-driven cost pressures may alter supplier selection and procurement practices, with implications for sourcing of active pharmaceutical ingredients, finished medicines, and surgical consumables used in endometriosis management. These dynamics can raise the administrative complexity of import-dependent supply lines and incentivize regional sourcing strategies.

Operational teams must anticipate how increased import costs could influence inventory policy, contracting cadence, and strategic stockpiles. Procurement groups may respond by seeking diversified supplier networks, negotiating longer-term agreements, or shifting toward larger consolidated purchases to mitigate volatility. Providers and specialty clinics should evaluate formulary implications as product economics change; meanwhile, manufacturers may consider localized manufacturing or tolling arrangements to preserve competitive pricing and minimize distribution friction.

From a patient access perspective, tariff-induced disruptions can reshape availability patterns across distribution channels and care settings. Transitional mitigation measures, such as advance purchase agreements, consolidated logistics, and collaborative sourcing among provider networks, can attenuate short-term impacts. Ultimately, stakeholders that proactively assess supply chain exposures and adapt procurement strategies will be better positioned to sustain uninterrupted care and preserve therapeutic choice for patients.

Insights into treatment segments, ROA, care settings, and distribution pathways that inform clinical priorities and service delivery for endometriosis

Meaningful segmentation illuminates where clinical needs diverge and where operational levers can be applied. When viewed through treatment type, endometriosis management spans Complementary Therapies, Hormonal Therapies, Pain Management, and Surgical Treatment. Hormonal Therapies encompass classes such as Aromatase Inhibitors, GnRH Agonists, GnRH Antagonists, Oral Contraceptives, and Progestins, each carrying distinct efficacy profiles, tolerability considerations, and monitoring needs. Pain Management strategies include the use of NSAIDs and Opioids, and the NSAID category itself is commonly represented by agents such as Diclofenac, Ibuprofen, and Naproxen, while opioid options frequently involve codeine and morphine derivatives; these choices implicate different safety monitoring and prescribing frameworks.

Route of administration is another critical differentiator, with injectable, oral, and topical modalities shaping adherence dynamics, clinic visit frequency, and supply logistics. End user settings also matter materially: ambulatory surgical centers, hospitals, and specialty clinics each offer different procedural capabilities, perioperative protocols, and patient throughput considerations that affect treatment sequencing. Distribution channels complete the segmentation picture, as hospital pharmacy, online pharmacy, and retail pharmacy pathways influence inventory management, patient access timelines, and opportunities for therapeutic counseling.

By synthesizing these layers, stakeholders can identify intervention points for clinical education, formulary design, and targeted service models. Strategic decisions that reflect the interplay between therapeutic class, administration route, care setting, and distribution pathway will more effectively meet heterogeneous patient needs and streamline operational execution.

Regional analysis of clinical practice, reimbursement frameworks, and patient access that contrasts the Americas, EMEA, and Asia-Pacific landscapes in endometriosis

Regional dynamics exert a strong influence on how endometriosis care is delivered and accessed, with meaningful variation in practice patterns, regulatory environments, and payer policies across major geographies. The Americas tend to reflect a mix of private and public payer arrangements, with centralized centers of excellence and growing adoption of minimally invasive surgical techniques, while access to new pharmacologic options varies according to payer policy and regional supplier relationships. By contrast, Europe, the Middle East & Africa display a heterogeneous mosaic of national healthcare systems, regulatory timelines, and reimbursement rules, leading to varied adoption rates for novel therapies and differing emphases on fertility-preserving approaches.

Asia-Pacific markets present additional diversity: some jurisdictions prioritize rapid adoption of innovative diagnostics and telehealth-enabled care pathways, while others face access constraints driven by supply chain complexity and differing reimbursement priorities. Across regions, the balance between hospital-centric procedures and ambulatory care alternatives affects where patients receive surgery and follow-up, and distribution channel maturity-from hospital pharmacy networks to rapidly growing online pharmacy services-shapes patient access to both acute and maintenance therapies.

Understanding these regional contrasts enables more precise allocation of resources, localized evidence generation, and commercially realistic access strategies. Stakeholders should tailor clinical support, pricing strategies, and supply models to regional regulatory imperatives and patient access realities to optimize outcomes and sustainability.

Companies operating in the endometriosis ecosystem are pursuing a range of strategic plays that impact innovation velocity and market dynamics. Established therapeutics manufacturers continue to optimize existing portfolios while selectively advancing next-generation hormonal agents and novel mechanisms that target pain and lesion progression. At the same time, smaller biopharma and device innovators focus on niche indications, adjunctive therapies, and technology-enabled diagnostics designed to improve time to diagnosis and personalize treatment selection.

Across the competitive landscape, partnership models-such as licensing agreements, co-development collaborations, and distribution alliances-are increasingly important for accelerating access and sharing developmental risk. Strategic positioning also extends to capabilities in real-world evidence generation and patient engagement programs, which influence payer negotiations and clinician adoption. Firms that invest in demonstrable outcomes, streamlined manufacturing footprints, and resilient supply chains will reduce barriers to adoption and build stronger payer and provider relationships.

Ultimately, corporate strategic choices around R&D prioritization, commercial models, and ecosystem partnerships will determine who can scale innovations most effectively. Companies that integrate clinical evidence with pragmatic deployment strategies and robust patient support systems will emerge best positioned to deliver sustainable impact across the patient journey.

Actionable recommendations for leaders to expedite diagnosis, refine therapeutic pathways, strengthen supply resilience, and elevate patient care in endometriosis

Actionable, prioritized steps can help organizations accelerate meaningful improvements in endometriosis care. First, invest in clinician and primary care education to reduce diagnostic delays and ensure consistent use of guideline-based referral pathways; earlier identification streamlines care and expands therapeutic options. Second, align evidence-generation strategies with payer priorities by emphasizing real-world outcomes, quality-of-life metrics, and comparative effectiveness to support coverage discussions and formulary inclusion.

Third, strengthen supply chain resilience by diversifying suppliers, exploring regional manufacturing options, and implementing strategic inventory practices to mitigate tariff or logistics disruptions. Fourth, design patient-centered service models that integrate pharmacologic management, pain control strategies, fertility counseling, and psychosocial support to address the multifaceted needs of individuals living with the condition. Fifth, leverage digital tools to facilitate remote monitoring, adherence support, and triage, thereby reducing unnecessary visits and enhancing continuity of care.

When implemented cohesively, these recommendations create a reinforcing cycle: better diagnosis and tailored therapies improve outcomes, which in turn support payer value arguments and stabilize revenue streams necessary for continued innovation. Leaders should prioritize interventions that deliver measurable clinical benefit while remaining operationally feasible within existing care infrastructures.

Clear description of research framework, data collection and validation processes, and analytical methods applied to derive insights on endometriosis care

This research applied a structured, multi-source approach to ensure the robustness and credibility of findings. Primary qualitative inputs included in-depth interviews with clinicians, procurement specialists, and patient advocates, complemented by secondary literature reviews of peer-reviewed clinical studies, regulatory guidances, and practice guidelines. Triangulation across these inputs was used to validate thematic findings and identify consistent patterns across clinical practice and operational decision-making.

Analytical methods combined qualitative synthesis with scenario-based supply chain mapping and stakeholder impact analysis. Validation protocols included cross-checking interview insights with publicly available regulatory documents and procedural standards, and applying sensitivity checks to assumptions about care delivery pathways. Wherever possible, the research emphasized transparent linkage between evidence sources and derived conclusions, enabling users to trace how specific insights were developed.

The methodology prioritized reproducibility, clarity of assumptions, and contextual interpretation rather than predictive quantification. Clear documentation of data sources, interview frameworks, and analytic logic supports downstream application by clinicians, commercial teams, and procurement professionals seeking to adapt the insights to their own operational contexts.

Concluding synthesis of key findings and implications setting priorities for stakeholders to improve diagnosis, care delivery, and patient outcomes in endometriosis

The concluding synthesis brings together clinical, operational, and commercial perspectives to clarify strategic priorities. Delays in diagnosis, heterogeneous adoption of therapeutic options, and supply chain vulnerabilities emerge as persistent themes that shape patient experience and system performance. In response, coordinated strategies that combine clinician education, evidence generation, resilient procurement, and patient-focused service design provide the most promising avenue for durable improvement.

Stakeholders should prioritize interventions that deliver tangible clinical benefit while also addressing logistical constraints that influence access and adherence. Examples include bolstering pathways for early specialist referral, aligning therapeutic value propositions with payer evidence needs, and investing in supply chain redundancies that reduce the risk of therapeutic interruptions. Importantly, integrating patient voice into research and service design amplifies relevance and can accelerate uptake through demonstrable improvements in quality of life.

In summary, the path forward requires multidisciplinary collaboration and pragmatic implementation. By aligning scientific innovation with operational realism and patient priorities, the sector can advance meaningful improvements in care delivery and outcomes for people affected by endometriosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endometriosis Treatment Market, by Treatment Type

  • 8.1. Complementary Therapies
  • 8.2. Hormonal Therapies
    • 8.2.1. Aromatase Inhibitors
    • 8.2.2. Gnrh Agonists
    • 8.2.3. Gnrh Antagonists
    • 8.2.4. Oral Contraceptives
    • 8.2.5. Progestins
  • 8.3. Pain Management
    • 8.3.1. Nsaids
      • 8.3.1.1. Diclofenac
      • 8.3.1.2. Ibuprofen
      • 8.3.1.3. Naproxen
    • 8.3.2. Opioids
      • 8.3.2.1. Codeine
      • 8.3.2.2. Morphine
  • 8.4. Surgical Treatment

9. Endometriosis Treatment Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Endometriosis Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Endometriosis Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Endometriosis Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endometriosis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endometriosis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Endometriosis Treatment Market

16. China Endometriosis Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amneal Pharmaceuticals Inc.
  • 17.7. Anika Therapeutics, Inc.
  • 17.8. Astellas Pharma Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Bayer AG
  • 17.11. Beijing Biote Pharmaceutical Co., Ltd.
  • 17.12. Eli Lilly and Company
  • 17.13. Ferring International Center S.A.
  • 17.14. Gedeon Richter Plc
  • 17.15. Janssen Pharmaceuticals
  • 17.16. Johnson & Johnson Services, Inc.
  • 17.17. Kissei Pharmaceutical Co., Ltd.
  • 17.18. Livzon Pharmaceutical Group Inc.
  • 17.19. Merck & Co., Inc.
  • 17.20. Myovant Sciences Ltd.
  • 17.21. Neurocrine Biosciences, Inc.
  • 17.22. Novartis AG
  • 17.23. ObsEva SA
  • 17.24. Pfizer Inc.
  • 17.25. Repros Therapeutics Inc.
  • 17.26. Sanofi S.A.
  • 17.27. Shionogi & Co., Ltd.
  • 17.28. Takeda Pharmaceutical Company Limited
  • 17.29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)